This metadata record and it's attached files make statements about the kinds of data collected as part of this research, and set out policies for governance of that data, now and in the future.
Description: The objective of this study is to investigate whether or not antidiabetic drugs influence the cellular metabolism of peripheral blood immune cells. Blood samples of up to 100 participants with type 2 diabetes will be collected before and around 12 weeks after starting a new antidiabetic treatment.
Blood samples will be analysed to determine if there is a correlation between successful anti-diabetic treatment, as assessed by decreased HbA1c and/or fasting plasma glucose, and any of the immunometabolic outcomes. Secondary analyses will explore whether the different anti-diabetic treatments influence cellular immunometabolism in different ways.
Publisher
University of AucklandTemporal coverage: start
2022-01-01HVN Project / Programme Name
HVN AntidiabeticData access requirements
Data will be made available upon publication.Principal investigator organisation
Malaghan Institute of Medical ResearchCollaborating researchers and affiliations
Principal Investigator:
Dr. Olivier Gasser, Translational Immunology Group Leader, Malaghan Institute of Medical Research
Wellington, New Zealand
Co-Investigators:
-Dr. David O’ Sullivan (Malaghan Institute of Medical Research)
-Sophie Faulkner (Malaghan Institute of Medical Research)
-Alix Grooby (Malaghan Institute of Medical Research)
-Rosemary Hall (Capital and Coast District Health)
-Jeremy Krebs (Capital and Coast District Health)Data description
Outcomes of the study and associated data
Primary Outcome
The correlation between changes in HbA1c levels and any antidiabetic treatment-induced changes in the oxygen consumption rate (OCR) to extracellular acidification rate (ECAR) ratio of activated PBMC, as measured by metabolic flux analysis.
Associated data: HbA1c, ratio of oxygen consumption rate (OCR) to extracellular acidification rate (ECAR) of activated PBMC (OCR:ECAR)
Secondary Outcomes
- Correlation between fasting plasma glucose and any antidiabetic treatment-induced changes in OCR to ECAR ratio of activated PBMC
- Correlation between changes in HbA1c levels and any antidiabetic treatment-induced changes in the metabolic programming of immune cell subsets as determined by immunometabolic flow cytometry
- Correlation between changes in fasting blood glucose levels and any antidiabetic treatment-induced changes in the metabolic programming of immune cell subsets as determined by immunometabolic flow cytometry
Associated data: Fasting plasma glucose, OCR:ECAR, HbA1c, immune cell populations including T and B cells, monocytes, dendritic cells and natural killer cells,
Other associated data: demographic, clinical information, medical history and anthropometry from electronic clinical recordsPrincipal investigator contact email
ogasser@malaghan.org.nz
